Онлайн КрасотаКаталог

Брошюра «Клинические исследования пептидных биорегуляторов» Электронная версия на английском языке — страница 118

Книги и пособия · 125 страниц · 0.7 МБ · Полное издание

Читать текстСкачать PDF
Pinealon Distribution of the patients by nosological groups, sex and age. Table 1 Diagnosis Age Men Women Total (years) Control group Main Control group Main Control group Main group group group Long-term effects of 35-65 5 7 1 1 6 8 craniocerebral injury State after stroke 56-75 5 6 1 3 6 9 Vascular 55-78 5 7 5 8 10 15 encephalopathies Signs of decreased 51-68 6 5 4 5 10 10 mental capacity, memory, attention. Total: 21 25 11 17 32 42 RESEARCH METHODS The effectiveness of PINEALON® was assessed by the dynamics of subjective indicators and objec- tively using the methods of proofreading and electroencephalography (EEG). RESEARCH RESULTS After administrating PINEALON® to patients of the primary group, a good clinical result was observed in 66.7% of cases, satisfactory - in 23.8%, no positive effect - in 9.5% of cases (in the control group - Table 2). There was no negative effect of PINEALON® on the condition of the patients. PINEALON® efficiency in patients with diseases of the central nervous system Table 2 Treatment results Group of patients Treatment using general purpose medication Treatment using “Pinealon” Abs. % Abs. % Good 9 28,1 28 66,7* Satisfactory 13 40,6 10 23,8 Not satisfactory 10 31,2 4 9,5* Total: 32 100 42 100 * Р<0,05 in comparison with the parameters after treatment using general purpose drugs. When comparing the subjective indicators of the state of patients before and after the use of PINE- ALON®, it was found that the number of health complaints decreased by 2-3 times. Patients noted an improvement in memory, intelligence, a decrease in the intensity and duration of headaches, the appearance of emotional balance, volitional qualities, and a sense of rest after a night’s sleep (Table 3). Patients with the consequences of craniocerebral injury and stroke noticed a moderate regression of focal symptoms, improved speech function with motor and sensory aphasia, and decreased mus- cle spasticity.

Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.

Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.